Novo Nordisk strikes second licensing deal since frosty capital-markets day

AI Summary

Novo Nordisk has signed its second licensing deal since investors reacted poorly to the company’s long-term strategy presentation. The report provides no details about the deal or the licensed product.

Novo Nordisk on Tuesday struck its second licensing deal since receiving a poor reception from investors after presenting its long-term strategy.